Search

Displaying results 5511 - 5520 of 10000 in total
  1. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.

  2. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. … As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.

  3. Drug

    Trandolaprilat

    go.drugbank.com/drugs/DB14209
    Experimental

    The active metabolite of the prodrug Trandolapril.

    Categories: Agents Acting on the Renin-Angiotensin System
  4. Drug

    FP-1096

    go.drugbank.com/drugs/DB05310
    Experimental

    FP1096 reduced the painful symptoms of endometriosis in trial subjects with very minimal side effect.

  5. Drug

    Alunacedase alfa

    go.drugbank.com/drugs/DB15736
    Investigational

    Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.

  6. Drug

    Polyinosinic-polycytidylic acid

    go.drugbank.com/drugs/DB16467
    Investigational

    Synonyms: Poly I-C, Poly(I+C)Categories: Poly I, Poly I-C
  7. Drug

    Cadralazine

    go.drugbank.com/drugs/DB13452
    Experimental

    Categories: Arteriolar Smooth Muscle, Agents Acting On
  8. Drug

    Bucetin

    go.drugbank.com/drugs/DB13278
    ApprovedWithdrawn

    Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]

  9. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. … moderate-to-severe asthma), NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in

  10. Drug

    Fidexaban

    go.drugbank.com/drugs/DB19562
    Experimental

    Fidexaban is a small molecule drug. The usage of the INN stem '-xaban' in the name indicates that Fidexaban is a blood coagulation factor XA​ inhibitor, antithrombotic. … Fidexaban has a monoisotopic molecular weight of 526.18 Da.